NanoViricides Reports NV-387 Shows Strong Antiviral Activity Against Measles in Preclinical Studies

NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical lead drug candidate, NV-387, demonstrated potent antiviral effects against the Measles virus in both cell culture studies and a humanized animal model. The treatment extended survival in infected mice by 130%, from 7.4 to 17 days, while significantly protecting lung tissue from viral and immune-related damage. This finding is particularly significant given that currently no approved drug exists for Measles treatment, underscoring NV-387's potential as a first-in-class therapeutic candidate.

The drug's dual action mechanism—direct viral suppression and mitigation of systemic and lung inflammation—showed reduced lung plaques, slower disease progression and improved overall health outcomes in treated animals. This comprehensive approach addresses both the viral infection itself and the damaging inflammatory response that often contributes to severe complications in Measles cases. The company's platform technology and programs are based on the TheraCour nanomedicine technology, which NanoViricides holds licenses for various viral diseases through its relationship with TheraCour Pharma, Inc.

NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. The company describes NV-387 as a broad-spectrum antiviral drug that they plan to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company's business model involves licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

The positive results against Measles add to the potential applications of NV-387, which the company intends to develop across multiple viral indications. Measles remains a significant global health concern despite available vaccines, with outbreaks continuing to occur in various regions. The development of an effective therapeutic could provide an important tool for managing cases in unvaccinated populations and controlling outbreaks. The company maintains its corporate information and updates through its official channels at https://www.nanoviricides.com where investors and interested parties can access current information about the company's progress and development pipeline.